Increasing evidence implicates human cytomegalovirus (HCMV) in the etiopathogenesis of breast cancer. Antibodies to this virus in patients with breast cancer have been reported, but no large-scale studies have been conducted to determine whether the antibody levels differ between patients and matched controls. Using specimens from a large (1712 subjects) multiethnic case-control study, we aimed to determine whether the levels of antibodies to the HCMV glycoprotein B (gB) differed between patients and controls and whether they were associated with particular immunoglobulin γ marker (GM), κ marker (KM), and Fcγ receptor (FcγR) genotypes. A combined analysis showed that anti-gB immunoglobulin G antibody levels were higher in healthy controls than in patients (P < .0001). Stratified analyses showed population-specific differences in the magnitude of anti-gB antibody responsiveness and in the contribution of particular GM, KM, and FcγR genotypes to these responses. These findings may have implications for HCMVbased immunotherapy against breast cancer and other HCMV-associated diseases.
Breast cancer is the most common cause of cancer-related death among women worldwide. Like other complex diseases, breast cancer is thought to result from both genetic and environmental factors. Several genes, including some belonging to the immune system, have been implicated in the etiopathogenesis of this malignancy. One putative environmental (ie, viral) factor that has received considerable attention is human cytomegalovirus (HCMV). Although HCMV is not considered an oncogenic virus at present, several features of HCMV biology overlap with the essential alterations of cell physiology, including tumor microenvironment, that are hallmarks of cancer, as enunciated by Hanahan and Weinberg [1] . Several HCMV proteins-US2, UL16, and IE2-and HCMV-encoded homologs to immunosuppressive cytokines (eg, interleukin 10) are involved in the evasion of host immunosurveillance. HCMV proteins such as IE1 and IE2 inhibit apoptosis, thus resisting cell death [2] . Although direct evidence that HCMV causes breast cancer is still lacking, the evidence that the virus is somehow involved in the progression of the disease is steadily growing [3] [4] [5] [6] [7] [8] . A recent investigation found that 100% of the primary breast cancer samples evaluated were HCMV positive and detected virus protein expression in neoplastic cells in sentinel lymph node metastases of breast cancer [6] .
HCMV-infected patients with breast cancer, as well as healthy individuals, generate both cellular and humoral immune responses to the virus. We hypothesized that if the host immune responses to the virus contributed to protection against cancer, healthy individuals should have higher levels of endogenous antibodies to HCMV than patients with cancers associated with HCMV infection. To test this hypothesis, we characterized a large number of multiethnic patients with breast cancer and matched controls for antibody responsiveness to HCMV glycoprotein B (gB), which is required for viral infectivity and is a major component of the viral envelope. We also aimed to determine whether the magnitude of anti-gB antibody responsiveness is influenced by certain genes of the immune system. The candidate genes chosen were those encoding immunoglobulin γ marker (GM) and κ marker (KM) allotypes-hereditary antigenic determinants of γ and κ chains, respectively-and Fcγ receptors (FcγRs) IIa and IIIa. Allelic variants of these genes have been implicated in immunity to several infectious pathogens [9] [10] [11] [12] [13] [14] [15] [16] . [17] . Briefly, patients with breast cancer were recruited between 2001 and 2005 at 4 hospitals in Nagano, Japan, and between 2001 and 2006 at 8 hospitals in São Paulo, Brazil. Cancer-free controls were matched to case patients by ethnicity, residential area during the study period, and age (within 3-5 years). The study protocol was approved by the institutional review boards of the respective institutions. Blood specimens were collected from cases and controls after they provided informed consent. Blood specimens were collected from patients before treatment. The study population consisted of 1712 subjects. Of the 911 subjects enrolled in Brazil, 510 were of European decent (hereafter, "white"), 82 were of African decent (hereafter, "black"), 159 were of Japanese decent (hereafter, "Japanese"), and 160 were of Brazilian mulatto decent (hereafter, "mulatto"). All 801 subjects recruited in Nagano were Japanese. Detailed data were collected on family history of cancer, menstrual and reproductive history, anthropometric factors, physical activity, and smoking habits. Estrogen and progesterone hormone receptor status was also determined.
Determination of Anti-HCMV gB Antibody Levels
Levels of immunoglobulin G (IgG) antibody to HCMV gB in sera from patients and controls were determined by a previously described enzyme-linked immunosorbent assay [18] . The quantity of anti-gB IgG antibody detected in respective serum samples was expressed as arbitrary units (AU) per milliliter.
GM and FcγR Genotyping
GM alleles (3, 17, 23+, 23−, 5, and 21) were previously determined by TaqMan and polymerase chain reaction/restriction fragment-length polymorphism (PCR-RFLP) genotyping methods [19] . The histidine (H)/arginine (R) alleles at position 131 of FcγRIIa and the phenylalanine (F)/valine (V) alleles at position 158 of FcγRIIIa were previously determined by TaqMan genotyping assays [17] .
KM Genotyping
The KM1 and KM3 alleles were previously determined [20] by a PCR-RFLP method [21] .
Statistical Analyses

Analysis of Combined Sample
We used linear regression models for testing associations between anti-HCMV gB IgG antibody levels and a set of covariates: case status, hormone receptor status, ethnicity, age, menopausal status, number of births, age at first birth, body mass index, alcohol drinking, smoking status, moderate physical activity in the past 5 years, vitamin supplement use, family history of breast cancer, history of benign breast disease, history of breastfeeding children, and age at menarche. We conducted univariate analyses and multivariate analyses. In univariate analyses, hormone receptor status (P < .0001), ethnicity (P < .0001), age (P < .0001), menopausal status (P < .0001), number of births (P < .0007), age at first birth (P < .0134), and body mass index (P < .0001) were associated with anti-gB antibody levels. Multivariate analyses using backward selection approach resulted in a model including case status (P < .0001), ethnicity (P = .0365), age (P < .0001), and body mass index (P = .0012). We confirmed that the association between antigB antibody levels and case status remained significant (P = .0018) even after adjustment for the genotypic effects at the 6 loci in the linear model (in addition to adjustment for ethnicity, age, and body mass index).
Analysis in Stratified Populations
We compared the anti-gB IgG antibody levels between patients and controls within each stratified population by using linear regression models. Based on the results from backward selection, we only adjusted for the covariates age and body mass index. In each stratified population, we also tested the main (marginal) effects of genotypes at 6 loci (3 GM loci, 2 FcγR loci, and the KM locus) on anti-gB IgG antibody levels in cases and controls separately. For each test, we used linear regression models and adjusted for the covariates age and body mass index. We considered a genotypic test and tests under 3 different genetic models: additive, dominant, and recessive.
Epistasis in Stratified Populations
We tested the interactive effects of the genotypes at 3 GM loci, 2 FcγR loci, and the KM locus. We used linear regression models and adjusted for the covariates age and body mass index. The best fitting model for interaction was chosen by using the Akaike information criterion. We also conducted 2-way analysis of variance (ANOVA) to confirm the significant epistases identified by the best-fitting models and estimated the predicted (mean) IgG antibody levels within different genotype combination categories. Significant epistases identified by the best-fitting models and confirmed in ANOVAs are presented below (Tables 3 and 4) . We only present P values from the ANOVAs that were more conservative than the analyses using linear regression models. All tests were 2-sided with an α of 0.05. For all associations, P values are given, with the caveat that they were not adjusted for multiple testing, so that the reader can make an informed judgment. Adjustments for multiple testing are controversial [22] , and we believe that, instead of performing such adjustment in this work, the best approach would be to test in an independent sample. Table 1 presents the anti-HCMV gB IgG antibody levels for 1712 patients with breast cancer and controls, by population. A combined analysis of all subjects showed that mean levels (±SD) of anti-gB IgG antibodies were significantly higher in cancer-free controls than in patients with breast cancer (834.1 ± 327.9 vs 767.2 ± 263.2 AU/mL; P < .0001). In stratified analyses, however, the anti-gB antibody levels showed significant differences between patients and controls in Japanese individuals but not in other groups. Among Japanese subjects, anti-gB antibody levels were significantly higher among controls, compared with patients with breast cancer (818.6 ± 193.1 vs 514.7 ± 218.7 AU/mL for subjects in Brazil [P < .0001] and 822.1 ± 366.6 vs 764.2 ± 257.1 AU/mL for subjects in Nagano [P = .0120]). We confirmed that the associations between anti-gB antibody levels and case status remained significant in Japanese in Brazil (P < .0001) and in Japanese in Nagano (P = .0346), even after adjustment for the genotypic effects at the 6 loci in the linear model (in addition to adjustment for ethnicity, age, and body mass index).
RESULTS
Anti-gB IgG Antibody Levels in Patients With Breast Cancer and Healthy Controls
Association of GM, FcγR, and KM Genotypes With Anti-gB IgG Antibody Levels
All genotypes were in Hardy-Weinberg equilibrium (P > .24) in all groups, except the mulatto population, which could be due to population admixture. This group was excluded from further analyses. In breast cancer cases, no markers showed a significant association with anti-gB IgG antibody levels in any group. In controls, the association between GM 3/17 genotypes and the level of anti-HCMV gB antibody responses was statistically significant under the additive, dominant, and recessive models in white subjects but not in other groups ( Table 2 ). The anti-HCMV gB antibody levels were highest in GM 17/17 homozygotes (904.95 ± 312.74 AU/mL), intermediate in GM 3/17 heterozygotes (851.94 ± 315.39 AU/mL), and lowest in GM 3/3 homozygotes (796.44 ± 275.60 AU/mL). The KM genotypes showed significant association under the dominant model (P = .0193) in Japanese Brazilians ( Table 2 ). The anti-gB antibody levels corresponding to KM 1/1, 1/3, and 3/3 genotypes were 833.13 ± 200.08, 870.19 ± 145.86, and 763.95 ± 224.75 AU/mL, respectively. No significant main effects were noted in any other control groups (data not shown).
Epistasis Effects of GM, FcγR, and KM Genotypes on Anti-gB IgG Antibody Levels in Patients With Breast Cancer Table 3 presents 3 dominant × additive epistatic interactions-GM 5/21 × KM 1/3, GM 5/21 × FcγRIIa R/H, and GM 5/ 21 × FcγRIIIa V/F-in black patients with breast cancer from Brazil. The reference alleles in these analyses are GM 5, FcγRIIa H, and FcγRIIIa V. Dominant × additive interaction is the best fitting model for our data, as determined by the Akaike information criterion. GM 5/21 genotypes, acting in a dominant fashion, interacted with additively acting KM 1/3 genotypes and significantly contributed to the levels of anti-gB IgG antibodies (P = .0311). Similarly, GM 5/21 genotypes, acting in a dominant fashion, interacted with additively acting FcγRIIa R/H and FcγRIIIa V/F genotypes and significantly contributed to the levels of anti-gB IgG antibodies (P = .0238 and P = .0228, respectively). Although these interactions are statistically significant, their biological significance is limited, owing to the small numbers for several genotypic combinations (this was the smallest cohort, with only 40 case-control pairs).
In the Japanese patients living in Nagano, we found a significant recessive × additive interactive contribution of GM 5/21 and KM 1/3 genotypes to the levels of anti-gB IgG antibodies (P ≤ .05). As shown in Table 3 , homozygosity for GM 5 and KM 3 alleles Table 1 Abbreviation: AU, arbitrary units. a For each stratified population, the P value was derived from tests based on linear regression models of anti-HCMV gB IgG antibody levels, with adjustment for the covariates age and body mass index. For the overall sample, the P value was derived from a test based on linear regression modeling, using the backward selection approach. was associated with highest levels of anti-gB IgG antibodies (877.9000 ± 104.4352 AU/mL), and homozygosity for GM 5 and heterozygosity at the KM locus resulted in the lowest levels (459.8000 ± 180.8871 AU/mL). No epistatic interactions were found in any other group of patients (data not shown).
Epistasis Effects of GM and FcγR Genotypes on Anti-gB IgG Antibody Levels in White Controls
In white controls, additive × recessive interactions were found between GM 3/17 and FcγRIIa R/H genotypes, where 3 and H were respective reference alleles (Table 4) . Thus, carriers of the FcγRIIa R allele (R/R or H/R) who were homozygous for GM 17 contributed the most to the levels of anti-gB IgG antibodies (969.6625 ± 42.9564 AU/mL), while those with homozygous genotypes for both the GM 17 allele and the FcγRIIa H allele contributed the least (744.4105 ± 68.2766 AU/mL; P = .0103). These subjects also showed a highly significant dominant x recessive interaction between GM 5/21 and FcγRIIa R/H genotypes (P = .0018). The carriers of the FcγRIIa R allele (R/R or H/R) who were homozygous for GM 21 allele contributed the most to the levels of anti-gB IgG antibodies (943.6429 ± 65.1176 AU/mL), while those with homozygous genotypes for both the GM 21 allele and the FcγRIIa H allele contributed the least Table 3 . (574.5445 ±99.4687 AU/mL). No epistatic interactions were found in any other group of controls (data not shown).
DISCUSSION
A combined analysis of all subjects showed that levels of antibodies to HCMV gB were significantly higher in cancer-free controls than in patients with breast cancer. This would appear to support our hypothesis that host immunity against HCMV could play a significant role in keeping people free of breast cancer. The differences in anti-gB antibody responsiveness between patients and controls, however, were not significant in all population groups examined. Several factors-such as the sample size, prevalence of HCMV, and population-specific host genetic factors-could have contributed to the divergent results in the stratified analyses. Results of our genetic analyses showed that alleles at the GM 3/17 locus, expressed on immunoglobulin γ1, additively contributed to the anti-gB antibody responsiveness, the antibody levels highest in GM 17 homozygotes, intermediate in the heterozygotes, and lowest in GM 3 homozygotes. This association in whites is especially noteworthy, as it independently confirms the results obtained using archived specimens from white control participants in the Upper Midwest Health Study [15, 23] . Putative mechanisms underlying this association may include possible GM 3/17-dependent conformational changes in the antigen-binding site in the immunoglobulin variable regions associated with anti-gB antibody specificity. GM 3/17 alleles are expressed in the CH1 region of the γ1 chain. Amino acid sequence polymorphism in this region has been shown to modulate the kinetic competence of antigen binding sites [24] . GM allotypes could also influence antibody responsiveness to gB through the B-cell-mediated antigen processing/presentation pathway. Perhaps the B-cell membrane-bound IgG molecules expressing GM 17/17 determinants constitute a higher-affinity receptor for the HCMV gB epitopes and are more efficient than those expressing GM 3/3 alleles in the uptake of these antigens and presenting them to collaborating helper T cells, thus resulting in higher B-cell activation.
If anti-HCMV antibodies were protective, subjects with the low-responder genotype-GM 3/3-would be expected to be at a higher risk of developing breast cancer than subjects with the high-responder genotypes. This is consistent with our report involving white subjects in this study population: compared with subjects who were homozygous for the GM 17 allele, the GM 3 homozygotes were over twice as likely to develop breast cancer [19] . In addition to their contribution to the magnitude of humoral immunity to HCMV gB, certain GM alleles appear to modulate an immunoevasion strategy of HCMV, which provides an additional mechanistic explanation for their involvement in the etiopathogenesis of breast cancer. We have shown that HCMV TRL11/IRL11-encoded decoy FcγR, which the virus uses for immunoevasion [25] , has significantly higher affinity for IgG1 proteins expressing the GM 3+,1-,2-allotypes than for those expressing the allelic GM 17+,1+,2+ allotypes [26] . Higher affinity of GM 3+,1-,2-expressing IgG1 to the TRL11-encoded FcγR would imply that subjects with GM 3+,1-,2-allotypes would be more likely to have their Fc domains scavenged, thereby reducing their immunological competence to eliminate the virus through Fc-mediated effector mechanisms. Consequently, subjects possessing the GM 3+,1-,2-allotypes would be expected to have an increased risk of developing HCMV-associated diseases [27] .
We found a significant association between KM 1/3 genotypes and anti-gB antibody responsiveness in Japanese control subjects living in Brazil. The heterozygotes had significantly higher level of antibodies than both homozygotes. Several mechanisms could account for this association. As with GM allotypes, KM allotypes could also influence antibody responsiveness through the B-cell-mediated antigen processing/presentation pathway: B-cell membrane-bound IgG (κ) molecules expressing KM 1/3 determinants might constitute a higher-affinity receptor for the gB epitopes. Significant linkage disequilibrium between particular variable and constant genes may provide yet another mechanism for the constant-region region KM determinants to indirectly (by "hitchhiking" with the variable-region markers) influence antibody responses controlled primarily by the variable-region genes. Both KM 1 and KM 3 alleles are associated with different variable-region determinants of the immunoglobulin κ chain [21] .
Several significant epistatic interactions between GM and KM genotypes and between particular GM and FcγR genotypes were noted, although the sample size for some of these comparisons was too small to be of wider biological significance. Therefore, large-scale multiethnic studies are warranted to confirm or refute these observations. If confirmed, these interactions could be explained by sound biological mechanisms. There is increasing evidence that epistasis-modification of the action of a gene by 1 or more other genes-plays a significant role in human diseases [28] [29] [30] [31] . Determinants expressed on heavy and light chains and those expressed on Fc and FcγR are probably some of the most likely candidate pairs for gene-gene interactions in the human genome. Thus, significant interaction between particular GM and KM genotypes may be a reflection of preferential association of heavy (γ) and light (κ) chains of particular genotypes in the synthesis of anti-gB IgG antibodies. Such nonrandom/ preferential pairing of heavy and light chains has been reported in animal models [32, 33] .
Simultaneous involvement of GM and FcγR alleles in endogenous anti-gB antibody responsiveness could be explained by a mechanism involving the antigen processing and presenting pathway. It is known that FcγR-mediated uptake of antigenantibody complexes can enhance antigen presentation [34] . Perhaps antigen-presenting cells expressing certain FcγR alleles preferentially uptake antigen-antibody complexes expressing certain GM allotypes and present them to collaborating helper T cells, thus resulting in higher B-cell activation. In this context, it is relevant to note that we have recently presented mechanistic evidence for epistatic interaction between particular GM and FcγR alleles in the outcome of infection with herpes simplex virus type 1 (HSV1) [16] .
We found racial differences in the magnitude of anti-gB antibody responsiveness and in its association with various genetic markers. The reasons for these differences are not clear. One contributory factor could be differences in HCMV seroprevalence, which has been shown to be associated with race [35] . Another factor could be the divergent allele frequencies at GM, KM, and FcγR loci among the racial groups examined in this investigation. Additionally, linkage disequilibrium between GM alleles in Japanese individuals is different from that in white or black individuals, resulting in distinct arrays of GM haplotypes in these groups [36] [37] [38] . It follows that linkage disequilibrium between any putative immune response genes for gB epitopes might also be different in these groups, contributing to the ethnic differences in genetic associations with antibody responses. Multiple genetic and nongenetic factors probably contribute to immune responsiveness to HCMV, and racial differences in these factors may contribute to the differences in the observed associations. This is the first study of its kind, and its findings need to be replicated. If confirmed, these results would suggest that higher levels of anti-gB antibodies play an important role in keeping people free of cancer, possibly through their participation in host immunosurveillance mechanisms, such as antibodydependent cellular cytotoxicity (ADCC), against HCMV-infected cells. This is plausible since ADCC also influences the clinical course of infection by a related herpesvirus, HSV1 [16] . It is also possible that these patients with breast cancer have low anti-gB IgG antibody levels because they have low IgG levels overall. Such a global decrease in IgG levels in this large multiethnic cohort is unlikely, but it cannot be excluded. We do not have data on immune responsiveness to other viruses or other HCMV proteins in this cohort, so we cannot be sure whether the observed responses are specific to HCMV gB.
Considering that endogenous antibody responses appear to be protective, therapeutic or prophylactic immunization with an HCMV vaccine (when available) might further boost host immunity and help people with breast cancer, as well as those at risk of developing this malignancy. Confirmation and further delineation of genetic associations reported here might lead to individualized immunotherapy against breast cancer by identifying people most likely to respond to such therapy.
The archived specimens used in this study were previously characterized for antibodies to cyclin B1, a tumor-associated antigen that is overexpressed in multiple types of cancer, including breast cancer. Cancer-free individuals had significantly higher levels of naturally occurring IgG antibodies to cyclin B1 than patients with breast cancer [39] . Thus, a more potent immunity to cancer-associated self/nonself factors in healthy individuals than in patients with cancer may be a general phenomenon, and more studies involving immunity to such factors are warranted to understand why approximately two thirds of the human population remains free of cancer [40] . Results of these studies may help devise novel therapeutic strategies leading to the eradication of a disease whose burden has doubled in the last 20 years.
Notes
